Seoul Pharma Co. Ltd (018680) — Cash Flow-to-Debt Ratio
Seoul Pharma Co. Ltd (018680) has a Cash Flow-to-Debt Ratio of -0.08x as of September 2025, meaning its operating cash flow of ₩-2.66 Billion could theoretically repay 0% of its total liabilities (₩32.70 Billion) in one year. Explore Seoul Pharma Co. Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Seoul Pharma Co. Ltd Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Seoul Pharma Co. Ltd across 13 annual periods. Also explore Seoul Pharma Co. Ltd total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Seoul Pharma Co. Ltd (2012–2024)
Year-by-year debt coverage analysis for Seoul Pharma Co. Ltd. For market capitalisation and broader financial context, see Seoul Pharma Co. Ltd market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.10x | ₩-3.01 Billion | ₩31.45 Billion | ▼ -145.0% |
| 2023 | 0.21x | ₩5.26 Billion | ₩24.74 Billion | ▲ +7447.2% |
| 2022 | 0.00x | ₩-78.21 Million | ₩27.01 Billion | ▲ +92.5% |
| 2021 | -0.04x | ₩-1.67 Billion | ₩43.29 Billion | ▼ -124.4% |
| 2020 | 0.16x | ₩5.74 Billion | ₩36.23 Billion | ▲ +129.4% |
| 2019 | 0.07x | ₩2.93 Billion | ₩42.44 Billion | ▲ +326.3% |
| 2018 | -0.03x | ₩-1.23 Billion | ₩40.25 Billion | ▲ +11.3% |
| 2017 | -0.03x | ₩-1.14 Billion | ₩33.08 Billion | ▲ +8.2% |
| 2016 | -0.04x | ₩-1.89 Billion | ₩50.47 Billion | ▼ -229.5% |
| 2015 | 0.03x | ₩1.42 Billion | ₩49.15 Billion | ▼ -6.3% |
| 2014 | 0.03x | ₩1.48 Billion | ₩47.88 Billion | ▲ +384.6% |
| 2013 | -0.01x | ₩-425.00 Million | ₩39.17 Billion | ▼ -104.2% |
| 2012 | 0.26x | ₩9.22 Billion | ₩35.29 Billion | — |